Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 165, Issue 8, 2014, Pages 635-646

  Kaur, Harpreet ^a   Jajodia, Ajay ^a   Grover, Sandeep ^a   Baghel, Ruchi ^a   Jain, Sanjeev ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Antipsychotics; Glutamatergic pathway; Pharmacogenomics; Phosphatidylinositol signaling; Schizophrenia; Severity

Indexed keywords

METABOTROPIC GLUTAMATE RECEPTOR 3; PHOSPHATIDYLINOSITOL PHOSPHATE 4-KINASE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, METABOTROPIC GLUTAMATE;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84923580602     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32268     Document Type: Article

References (76)

1. Albalushi T1, Horiuchi Y, Ishiguro H, Koga M, Inada T, Iwata N, Ozaki N, Ujike H, Watanabe Y, Someya T, Arinami T. 2008. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am J Med Genet B Neuropsychiatr Genet 147(3):392-396.
2. American Psychiatric Association. 1997. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154:1-63.
3. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
4. Battaglia G, Bruno V, Ngomba RT, Di Grezia R, Copani A, Nicoletti F. 1998. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur J Pharmacol 356(2-3):271-274.
5. Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. 2010. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res 117(1):92-98.
6. Bianchi MG, Bardelli D, Chiu M, Bussolati O. 2014. Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease. Cell Mol Life Sci 71(11):2001-2015.
7. Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, Yu S, Fang Y, Zhang C. 2013. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl) 230(1):49-55.
8. Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S. 2009. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 113(1):34-40.
9. Chen Q, He G, Chen Q, Wu S, Xu Y, Feng G, Li Y, Wang L, He L. 2005. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 73(1):21-26.
10. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15(1):111-117.
11. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard FP, Maurice K, Essioux L, Millasseau P, Grel P, Debailleul V, Simon AM, Caterina D, Dufaure I, Malekzadeh K, Belova M, Luan JJ, Bouillot M, Sambucy JL, Primas G, Saumier M, Boubkiri N, Martin-Saumier S, Nasroune M, Peixoto H, Delaye A, Pinchot V, Bastucci M, Guillou S, Chevillon M, Sainz-Fuertes R, Meguenni S, Aurich-Costa J, Cherif D, Gimalac A, Van Duijn C, Gauvreau D, Ouellette G, Fortier I, Raelson J, Sherbatich T, Riazanskaia N, Rogaev E, Raeymaekers P, Aerssens J, Konings F, Luyten W, Macciardi F, Sham PC, Straub RE, Weinberger DR, Cohen N, Cohen D. 2002. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 99(21):13675-13680.
12. Cremona O, Di Paolo G, Wenk MR, Lüthi A, Kim WT, Takei K, Daniell L, Nemoto Y, Shears SB, Flavell RA, McCormick DA, De Camilli P. 1999. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99(2):179-188.
13. Danbolt NC. 2001. Glutamate uptake. Prog Neurobiol 65(1):1-105.
14. de Graaf P, Klapisz EE, Schulz TK, Cremers AF, Verkleij AJ, van Bergen en, Henegouwen PM. 2002. Nuclear localization of phosphatidylinositol 4-kinase beta. J Cell Sci 115(Pt 8):1769-1775.
15. Deng X, Shibata H, Ninomiya H, Tashiro N, Iwata N, Ozaki N, Fukumaki Y. 2004. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 4:21.
16. Deng X, Shibata H, Takeuchi N, Rachi S, Sakai M, Ninomiya H, Iwata N, Ozaki N, Fukumaki Y. 2007. Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B(3):271-278.
17. Deng X, Sagata N, Takeuchi N, Tanaka M, Ninomiya H, Iwata N, Ozaki N, Shibata H, Fukumaki Y. 2008. Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia. BMC Psychiatry 8:58.
18. Dupont WD. 1988. Power calculations for matched case-control studies. Biometrics 44(4):1157-1168.
19. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR. 2004. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 101(34):12604-12609.
20. Fedorenko O, Tang C, Sopjani M, Föller M, Gehring EM, Strutz-Seebohm N, Ureche ON, Ivanova S, Semke A, Lang F, Seebohm G, Lang UE. 2009. PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacology (Berl) 206(3):429-435.
21. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP. 2009. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 9(5):311-318.
22. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N, Shibata A, Ninomiya H, Tashiro N, Fukumaki Y. 2003. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 13(2):71-76.
23. Godi A, Pertile P, Meyers R, Marra P, Di Tullio G, Iurisci C, Luini A, Corda D, De Matteis MA. 1999. ARF mediates recruitment of PtdIns-4-OH kinase-beta and stimulates synthesis of PtdIns(4, 5)P2 on the Golgi complex. Nat Cell Biol 1(5):280-287.
24. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. 2002. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51:493-497.
25. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y, Chauhan C, Verma B, Manduva V, Mukherjee O, Purushottam M, Sharma A, Jain S, Brahmachari SK, Kukreti R. 2009. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10(3):385-397.
26. Gupta M, Jain S, Moily NS, Kaur H, Jajodia A, Purushottam M, Kukreti R. 2012. Genetic studies indicate a potential target 5-HTR(3B) for drug therapy in schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet 159B(8):1006-1008.
27. Gupta M, Moily NS, Kaur H, Jajodia A, Jain S, Kukreti R. 2013. Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients. Genomics 102(2):131-135.
28. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. 2008. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 22(3):308-322.
29. Horiuchi Y, Iida S, Koga M, Ishiguro H, Iijima Y, Inada T, Watanabe Y, Someya T, Ujike H, Iwata N, Ozaki N, Kunugi H, Tochigi M, Itokawa M, Arai M, Niizato K, Iritani S, Kakita A, Takahashi H, Nawa H, Arinami T. 2012. Association of SNPs linked to increased expression of SLC1A1 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 159B(1):30-37.
30. Iwayama-Shigeno Y, Yamada K, Itokawa M, Toyota T, Meerabux JM, Minabe Y, Mori N, Inada T, Yoshikawa T. 2005. Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 378(2):102-105.
31. Javitt DC. 2004. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11):984-997 979.
32. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301-1308.
33. Kane JM. 1989. The current status of neuroleptic therapy. J Clin Psychiatry 50(9):322-328.
34. Karlsson RM, Tanaka K, Heilig M, Holmes A. 2008. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry 64(9):810-814.
35. Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S, Kukreti R. 2014. Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients. PLoS One 9(7):e102556.
36. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. 2005. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179(1):303-309.
37. Leucht S, Engel RR. 2006. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacol 31(2):406-412.
38. Lehman AF, Lieberman JA, Dixon LB. American Psychiatric Association Steering Committee on Practice Guidelines. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(suppl 2):1-56.
39. Lovinger DM, McCool BA. 1995. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73(3):1076-1083.
40. Lu W, Wu H, Cai J, Wang Z, Yi Z, Yu S, Fang Y, Zhang C. 2013. Lack of association of SLC1A1 variants with schizophrenia in Chinese Han population. Psychiatry Res 210(2):669-671.
41. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. 1959. Study of a new schizophrenomimetic drug; Sernyl. AMA Arch Neurol Psychiatry 81(3):363-369.
42. Lyon L, Kew JN, Corti C, Harrison PJ, Burnet PW. 2008. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse 62(11):842-850.
43. Makino C, Fujii Y, Kikuta R, Hirata N, Tani A, Shibata A, Ninomiya H, Tashiro N, Shibata H, Fukumaki Y. 2003. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am J Med Genet B Neuropsychiatr Genet 116B(1):17-22.
44. Masson J, Sagne C, Hamon M, El Mestikawy S. 1999. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51(3):439-464.
45. McCullumsmith RE, Meador-Woodruff JH. 2002. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26(3):368-375.
46. Meltzer HY. 2008. Schizophrenia. In: Ebert MH, Loosen PT, Nurcombe B, Leckman JF, editors. Current diagnosis & treatment: Psychiatry. New York: McGraw-Hill.
47. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
48. Moghaddam B, Adams BW. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281(5381):1349-1352.
49. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4):427-436.
50. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, White BC. 2006. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241(2):252-261.
51. Mössner R, Schuhmacher A, Schulze-Rauschenbach S, Kühn KU, Rujescu D, Rietschel M, Zobel A, Franke P, Wölwer W, Gaebel W, Häfner H, Wagner M, Maier W. 2008. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur Neuropsychopharmacol 18(10):768-772.
52. Nayak RK, Doose DR, Nair NP. 1987. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 27(2):144-150.
53. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH. 2004. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89(4):876-885.
54. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13(9):1102-1107.
55. Pin JP, Duvoisin R. 1995. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 34(1):1-26.
56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559-575.
57. Riva MA, Tascedda F, Lovati E, Racagni G. 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50(1-2):136-142.
58. Roth MG. 2004. Phosphoinositides in constitutive membrane traffic. Physiol Rev 84(3):699-730.
59. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. 1996. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16(3):675-686.
60. Schirmbeck F1, Nieratschker V, Frank J, Englisch S, Rausch F, Meyer-Lindenberg A, Rietschel M, Zink M. 2012. Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents. Psychiatr Genet 22(5):245-252.
61. Schooler NR, Levine J. 1976. Initiation of long-term pharmacotherapy in schizophrenia - Dosage and side-effect comparisons between oral and depot fluphenazine. Pharmakopsychiatr Neuropsychopharmakol 9(4):159-169.
62. Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. 2013. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr Res 144(1-3):1-8.
63. Skowronek MH, Georgi A, Jamra RA, Schumacher J, Becker T, Schmael C, Paul T, Deschner M, Höfels S, Wulff M, Schwarz M, Klopp N, Illig T, Propping P, Cichon S, Nöthen MM, Schulze TG, Rietschel M. 2006. No association between genetic variants at the ASCT1 gene and schizophrenia or bipolar disorder in a German sample. Psychiatr Genet 16(6):233-234.
64. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. 2001. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158(9):1393-1399.
65. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71(4):877-892.
66. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989.
67. Takaki H, Kikuta R, Shibata H, Ninomiya H, Tashiro N, Fukumaki Y. 2004. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 128B(1):6-14.
68. Tascedda F1, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA. 2001. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50(2):117-122.
69. Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, Bieńkowski P, Mierzejewski P, Potemkowski A, Samochowiec J. 2012. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol Rep 64(3):528-535.
70. Tzingounis AV, Wadiche JI. 2007. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci 8(12):935-947.
71. van Os J, Kapur S. 2009. Schizophrenia. Lancet 374(9690):635-645.
72. Walch-Solimena C, Novick P. 1999. The yeast phosphatidylinositol-4-OH kinase pik1 regulates secretion at the Golgi. Nat Cell Biol 1(8):523-525.
73. Weis S, Llenos IC, Dulay JR, Verma N, Sabunciyan S, Yolken RH. 2007. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm 114(2):261-271.
74. Wiedemann C, Schafer T, Burger MM. 1996. Chromaffin granule-associated phosphatidylinositol 4-kinase activity is required for stimulated secretion. EMBO J 15(9):2094-2101.
75. Wilmsdorff MV1, Blaich C, Zink M, Treutlein J, Bauer M, Schulze T, Schneider-Axmann T, Gruber O, Rietschel M, Schmitt A, Falkai P. 2013. Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World J Biol Psychiatry 14(7):490-499.
76. Woods SW. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64(6):663-667.